Financials in USD. Standardized financial statements.
A compact view of how INNOCAN PHARMA Corp turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $26.61M | $29.44M | $13.66M | $2.56M | $196,000 | $8,000 | $0 | $0 |
| Revenue Growth? | -9.6% | +115.5% | +433.7% | +1205.6% | +2350.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $2.68M | $3.25M | $1.68M | $452,000 | $75,000 | $5,000 | $23,534 | $0 |
| Gross Profit? | $23.93M | $26.19M | $11.98M | $2.11M | $121,000 | $3,000 | -$23,534 | $0 |
| Gross Margin? | +89.9% | +89.0% | +87.7% | +82.3% | +61.7% | +37.5% | 0.0% | 0.0% |
| Operating Expenses? | $25.19M | $27.43M | $8.18M | $8.37M | $7.60M | $4.73M | $3.00M | $1.17M |
| Operating Income? | -$1.25M | -$1.25M | $3.80M | -$6.27M | -$7.48M | -$4.72M | -$3.00M | -$1.17M |
| EBITDA? | $130,000 | -$1.21M | -$3.77M | -$3.70M | -$7.37M | -$4.93M | -$2.98M | $0 |
| Income Before Tax | $85,000 | $919,000 | -$4.03M | -$3.89M | -$10.09M | -$9.95M | -$3.33M | -$1.19M |
| Income Tax Expense | $426,000 | $1.18M | $214,000 | $1,000 | $0 | $0 | $0 | -$161,141 |
| Net Income? | -$1.12M | -$1.83M | -$4.70M | -$3.76M | -$10.05M | -$9.95M | -$3.33M | -$1.19M |
| EPS? | $-0.25 | $-0.42 | $-1.19 | $-0.98 | $-2.91 | $-3.99 | $-1.51 | $-0.54 |
| Diluted EPS? | $-0.25 | $-0.42 | $-1.19 | $-0.98 | $-2.91 | $-3.99 | $-1.51 | $-0.54 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality